Flagship explainer
What drives ADAPTIMMUNE THERAPEUTICS PLC’s return on equity?
ROE is five filed business factors multiplied together.
| Input | Value | Fiscal year | Source |
|---|---|---|---|
| −$70.8M | FY2024 |
| |
| Income before tax | −$67.2M | FY2024 |
|
| Operating income | −$68.8M | FY2024 |
|
| $178M | FY2024 |
| |
| Ending assets | $246M | FY2024 |
|
| Beginning assets | $283M | FY2023 |
|
| $11.8M | FY2024 |
| |
| $39.5M | FY2023 |
|
Source:
- SEC filingFiling detailsAccession 0001558370-25-003544